Legal proceedings against Pall Corporation
17 Feb 2006
Legal proceedings against Pall Corporation
Nottingham, UK, 17 February 2006 - Innovata plc (LSE: IOV) announces that, as part of ongoing legal proceedings brought against Pall Corporation by Innovata's subsidiary, Quadrant, for breach of contract, Pall has, at a late stage in the proceedings, indicated its intention to apply to the Court for permission to introduce a counterclaim. Innovata's initial view of this proposed counterclaim is that it is without merit and Innovata continues to pursue its substantial claim against Pall.
Contacts:
Innovata plc
Tel: 0115 974 474
Kieran Murphy, Chief Executive Officer
Peter Shennan, Finance Director
Financial Dynamics
Tel: 020 7831 3113
Sarah MacLeod / John Gilbert
Notes to Editors
About Innovata plc
Innovata plc specialises in the development of pulmonary products for the treatment of respiratory disorders and other serious diseases. Using its proprietary dry powder inhaler and drug formulation technologies, Innovata plc has developed a substantial portfolio of 13 marketed and clinical-stage products and has partnered with a number of pharmaceutical companies including Baxter, Merck KGaA, Celltech (part of UCB) and Otsuka.
Innovata plc was formed in July 2005 when ML Laboratories PLC acquired Quadrant Technologies Limited. The company has over 90 employees of whom 65 are engaged in research and development, mainly based at Innovata's headquarters in Ruddington, Nottingham, United Kingdom. The Company is listed on the London Stock Exchange under the symbol IOV.
Adept
A number of physical barriers have been developed for use during surgery to help prevent adhesions. However, these have had limited uptake in open surgery and are generally difficult to use in laparoscopic surgery. One key challenge is that these physical barriers (gels, sprays or film-like sheets placed between neighbouring organs in the peritoneal cavity) may reduce adhesions where they are placed, but do not prevent adhesions developing elsewhere in the abdomen. The ideal adhesion-reduction agent should be easy to use in all types of surgical procedure and capable of reducing adhesion formation at the operating site and throughout the peritoneum. Ongoing research suggests that AdeptŪ (icodextrin 4%) may be closest to this ideal profile. A non-viscous liquid, Adept can be used for both open and laparoscopic surgery, and is compatible with a wide range of antibiotics used during and after surgery. Adept is simple to use, being instilled slowly at the end of surgical procedures and used during surgery as an irrigant with a 1.5 litre bag of Adept (enabling 500ml to be used during procedures with 1000ml remaining for instillation at the end of surgery).
